Industry
Biotechnology
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 5:23 am
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 5:19 am
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 8:36 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 8:29 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 9:04 pm
Portfolio Pulse from Benzinga Insights
April 19, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 4:16 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 10:13 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.